GENERIC NAME: canagliflozin
BRAND NAME: Invokana
DRUG CLASS AND MECHANISM: Canagliflozin is an oral drug that reduces blood sugar (glucose) levels in patients with type 2 diabetes. It is a new type of diabetes medication in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. Under normal conditions, glucose is filtered out of the blood and into the kidney tubules as blood passes through the kidneys. The glucose then as absorbed from the tubules back into the blood so that glucose is not lost in the urine. SGLT2 is an enzyme in the kidney tubule that causes glucose to be reabsorbed from urine. Canagliflozin blocks the action of SGLT2. Therefore, canagliflozin reduces the reabsorption of glucose from renal tubules, leading to more excretion of glucose in urine. Canagliflozin was approved by the FDA in March 2013.
GENERIC AVAILABLE: No
PREPARATIONS: Tablets: 100 and 300 mg
STORAGE: Tablets should be stored at room temperature, 15 C to 30 C (59 F to 86 F)
DOSING: Canagliflozin should be taken before the first meal of the day. The recommended starting dose is 100 mg once daily and the maximum dose is 300 mg once daily. Renal function should be assessed prior to starting canagliflozin and periodically during treatment, and the dose of canagliflozin should be modified based on renal function.
Medically Reviewed by a Doctor on 4/10/2013
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index